SUPN Supernus Pharmaceuticals Inc.

25.67
-0.92  -3%
Previous Close 26.59
Open 26.38
Price To Book 2.58
Market Cap 1,346,366,754
Shares 52,449,036
Volume 421,359
Short Ratio
Av. Daily Volume 540,517
Stock charts supplied by TradingView

NewsSee all news

  1. Supernus to Present at the 2019 Cantor Global Healthcare Conference

    ROCKVILLE, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  2. Supernus to Present at Two September Healthcare Conferences

    ROCKVILLE, Md., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
NDA filing due 2H 2019.
SPN-812 (P301)
ADHD
Phase 3 data due 4Q 2019.
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine
FDA approval announced December 14, 2018 to expand label to include monotherapy treatment.
Oxtellar XR
Epilepsy
Phase 3 data trial to be initiated 4Q 2019.
SPN-604
Bipolar depression
Phase 3 data due 1Q 2020.
SPN-810 (P302)
Attention Deficit Hyperactivity Disorder (ADHD)

Latest News

  1. Supernus to Present at the 2019 Cantor Global Healthcare Conference

    ROCKVILLE, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  2. Supernus to Present at Two September Healthcare Conferences

    ROCKVILLE, Md., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system